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Introduction  
Autoimmunity 
Autoimmunity is the breakdown of immune self-tolerance (1) 
and can occur in an organ-specific or systemic manner. Organ-
specific autoimmunity is characterized by a T-cell or antibody me-
diated attack on a specific organ, whereas systemic autoimmunity 
is an uncontrolled immune response towards ubiquitous self-anti-
gens (1,2). Under homeostatic conditions, central and peripheral 
tolerance aid in eliminating auto-reactive T and B cells. While in 
the thymus or bone marrow, T cells and B cells, respectively, un-
dergo checks to determine their self-reactivity (3). Central toler-
ance is the elimination of auto-reactive T cells and B cells, in the 
thymus and bone marrow, respectively; it recognizes self-antigens 
with a strong affinity (2,4,5).  The main mechanism of central tol-
erance is negative selection. Negative selection allows the elimi-
nation of developing T cells and B cells if the corresponding recep-
tor on T cells (TCR) or on B cells (BCR) recognizes a self-antigen 
with high affinity (4–7). Additionally, B cells undergo receptor ed-
iting to avoid deletion. Receptor editing is the re-arrangement of 
genes that encode the BCR and thus allow the expression of a BCR 
with low affinity towards self-antigens (5,8). T cells and B cells 
that are able to recognize self-antigens with a low affinity are able 
to leave the thymus and bone marrow, respectively (5). At this 
point, peripheral tolerance including anergy as well as regulatory 
T  cells and B cells steps in and aids in the regulation of auto-reac-
tive cells (9–13). 
 
Human T lymphocytes 
Within the T cell group, multiple subsets exist, including CD4+ 
T helper (Th), CD8+ cytotoxic T cells (CTL), natural killer T cells 
(NKT cells) and regulatory T cells (Tregs) (14). All these subsets 
play an important role within the immune system. However, only 
CD4+ T cells and regulatory T cells will be discussed here.  
 
Th1 / Th2 
 To stimulate a naïve CD4+ T cell (Th0), both the TCR and the 
co-stimulatory molecules are needed to be stimulated. This oc-
curs by interaction between antigen presenting cells (APC) and 
Th0 cells (14). However, it is the local cytokine milieu that will de-
termine whether a Th0 cell will become a Th1 or a Th2 cell  (14–
16). Figure 1 summarizes the differential pathways of a naïve 
CD4+ T cell. It was Mosmann et al that initially coined the term 
‘Th1 and Th2’ (17,18). Classically, Th1 cells will produce inter-
feron-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and in-
terleukin-2 (IL-2), whereas Th2 cells are known to secrete IL-4, IL-
5, IL-10, and IL-13 (15,17–20). The presence of IL-12 and IFN-γ will 
activate signal transducer and transcription activator 4 (Stat4) and 
Stat1 signalling pathways, respectively, which induces T-bet ex-
pression, thus promoting Th1 cellular differentiation (21–23). For 
Th2 differentiation, exogenous IL-4 induces GATA3 via the Stat6 
signalling pathway (22,24,25). IL-2 acting via Stat5 signalling path-
way is also needed for full Th2 differentiation (22,26).  
 Once fully differentiated, IFN-γ and IL-4 are needed to am-
plify and augment pre-existing Th1 and Th2 cellular populations, 
respectively (15,22,27). This will allow for a Th1 or Th2 dominated 
immune response. It is known that Th1 and Th2 cells can cross-
regulate each other and that this cross-regulation can occur on a 
cytokine and transcriptional level (22). IFN-γ secreted by Th1 cells 
can suppress the expansion and effector function of Th2 cells. Ad-
ditionally, IL-4 produced by Th2 cells can exert the same regula-
tory function on Th1 cells (15,22,28). On a transcriptional level, T-
bet can suppress Th2 differentiation by preventing GATA3 from 
binding to the Th2 cytokine gene locus and inhibit cytokine pro-
duction, which would lead to Th2 differentiation (22,29). On the 
other hand, GATA3 has been shown to downregulate Stat4, which 
is crucial for Th1 development (22,30). One study by Usui et al has 
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suggested that Th1 differentiation occurs because T-bet sup-
presses GATA3 instead of amplifying the IFNG gene (31).  
 Th1 and Th2 cells are functionally distinct. Where Th1 cells 
aid in the combat of intracellular bacteria, such as mycobacterial 
infections, and viruses, Th2 cells help with extracellular parasites 
such as helminths (15,18,20,22,23). However, if these responses 
are not regulated, exaggerated Th1 responses have been linked 
with several organ-specific autoimmune diseases and exagger-
ated Th2 responses have been shown to play a crucial role in the 
development of allergic inflammation and asthma (20,32).  
 
 
Figure 1 Summary of the differentiation pathways of a naïve CD4+ T cells.  
 
Th17 cells 
The discovery of a third Th subset, namely Th17, caused a 
shift in the classical Th1 and Th2 paradigm. The third Th cell sub-
set is termed ‘Th17’ due to its ability to produce the cytokine IL-
17A and IL-17F (33,34). These cells also produce IL-21, IL-22, and 
IL-26 (35). IL-17 is thought to be a pro-inflammatory cytokine that 
is able to induce local inflammation by stimulating the production 
of IL-6 as well as amplifying local inflammation by synergizing 
with other pro-inflammatory cytokines such as IL-1β, IFN-γ and 
TNF-α (36). The cytokines produced by Th17 cells have effects on 
numerous immune and non-immune cells, some of which include 
epithelial cells, NK cells, B cells, macrophages, and neutrophils 
(35). The primary function of Th17 cells is to provide protection to 
the host by aiding in the clearance of extracellular bacteria and 
fungi (37). However, Th17 cells have also been linked to various 
autoimmune diseases, such as rheumatoid arthritis (RA), psoria-
sis, inflammatory bowel disease, multiple sclerosis, and autoim-
mune thyroid disease (38–41).  
 The differentiation of human Th17 cells from Th0 cells is still 
unclear. Several cytokines including IL-1β, IL-6, IL-21, IL-23, TNF-α 
and transforming growth factor-beta (TGF-β) have been involved 
in the differentiation of human Th17 cells either in combination 
or alone (42–46). The exact effect of IL-23 on human Th17 cells is 
not yet clear. In mice, it is known that IL-23 is upregulated only af-
ter cellular activation (33) and may have a role within Th17 ex-
pansion and pathogenicity, but in humans its central role may 
only be to direct Th17 differentiation (16,46).    
 The role of TGF-β in Th17 differentiation is truly fascinating. 
Until recently, TGF-β has been associated with regulatory T cells 
(Tregs) and not Th17 differentiation. Several groups have re-
ported that TGF-β is crucial to Th17 differentiation (42,44,46,47). 
However, TGF-β may not have a direct role in Th17 differentia-
tion, but instead it may limit Th1 differentiation and thereby al-
low the differentiation of Th17 cells (48). Further investigation is 
needed to clarify the role of TGF-β in Th17 differentiation. 
 Human Th17 cells express the transcription factor retinoic 
acid receptor-related orphan receptor C (RORC) (49,50), which 
distinguishes these cells from the prototypical Th1 and Th2 cells 
(51). RORC is the human ortholog to the mouse RORyt (37).The 
cytokines IL-1β, IL-6, IL-23, and TGF-β are all able to induce the 
expression of RORC in Th17 cells (37,44,45,52).  
 
Regulatory T cells  
Tregs are crucial in maintaining homeostasis within the im-
mune system (13). Tregs help to prevent an immune response 
against self-antigens as well as to suppress an immune response 
against exogenous antigens before they can become a danger to 
the host (10,53). Regulatory T cells consist of a heterogeneous 
population of cells including CD4+ T cells, CD8+ T cells and NK 
cells (54). However, only natural and inducible Tregs which are 
CD4+ will be discussed here.  
 Natural Tregs (nTregs) are developed in the thymus and mi-
grate to the periphery (54). These Tregs are characterized by the 
surface markers CD4, CD25 (9), cytotoxic T-lymphocyte-associ-
ated protein 4 (CTLA-4), and glucocorticoid-induced tumor-necro-
sis-factor-receptor-related protein (GITR) (54,55). Additionally, 
the transcription factor, forkhead box protein 3 (FOXP3), is im-
portant in the identification and development of nTregs (56–58). 
The cytokine TGF-β is reportedly able to enhance the expression 
of FOXP3, and is thus vital in the maintenance of nTregs (54). The 
specificity of the TCR on nTregs is towards self-antigens that are 
present in the thymus (53).This allows nTregs to suppress auto-re-
active T cells and B cells by cell-contact dependent mechanisms 
(53,59), and one of the core methods of suppression is the ex-
pression of CTLA-4. CTLA-4 regulates the co-stimulatory markers 
CD80/CD86 (59–61) and by binding to CD80/CD86, CTLA-4 gives 
the inhibitory signals which will prevent T cell activation (59,61). 
Normally, CD80/CD86 binds to CD28 and provides the necessary 
co-stimulatory signals to allow for T cell activation (62). In addi-
tion, nTregs may act like a ‘sink’ for the available IL-2 in the micro-
environment, which will result in the apoptosis or downregulation 
of effector T cells. This is because IL-2 is needed for effector T cell 
survival and growth, but also for the activation of nTregs and the 
upregulation of FOXP3 expression (54,59,63–65). 
 Inducible Tregs (iTregs), also known as adaptive Tregs, differ-
entiate from effector (CD4+CD25-) T cells into iTregs in the pe-
riphery (10,53,66). iTregs are identified based on their ability to 
secrete IL-10 and TGF-β (10,67,68). There is speculation that 
iTregs are not one heterogeneous population, but are sub-divided 
into two populations named Tr1 and Th3, the difference being the 
cytokines that they secrete. Tr1 cells are thought to secrete 
mainly IL-10, whereas Th3 cells secrete predominately TGF-β 
(66,69). The conversion of effector (CD4+CD25-) T cells into iTregs 
is achieved after antigen recognition and with help from CTLA-4, 
TGF-β or IL-10 (54,68,70–72) and after stimulation through CD46 
(73). Unlike nTregs, the suppression method for iTregs is cytokine 
dependent and is carried out via the secretion of IL-10 and TGF-β 
(10,53,70,72). The suppressive effects of IL-10 and TGF-β are mul-
tifaceted. Indirectly, iTregs, via IL-10 and TGF-β, can affect the 
function, cytokine production, and co-stimulatory molecule ex-
pression of APC, which would subsequently affect the cytokine 
production and proliferative capability of CD4+ T cells. Directly, 
iTregs, via IL-10 and TGF-β, can affect the cytokine production of 
CD4+ T cells (74–78)(10,68). Although, the main suppressive 
mechanism of iTregs is cytokine-dependent, there is some data 
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that indicate that iTregs may upregulate inhibitory receptors that 
could inhibit APC or CD4+ T cells on a cell-to cell contact basis 
(10,53).  
 
Figure 2 Regulatory T cell subsets.  
 
 Difficulty arises when trying to discern nTregs from iTregs or 
even from effector (CD4+CD25-) T cells, due to the similarities in 
the expression of certain surface markers. iTregs have been 
shown to acquire the expression of CD25 and FOXP3 (79), while 
nTregs, normally cytokine independent, can induce and secrete 
IL-10 and/or TGF-β (80–82). Studies have also demonstrated that 
effector (CD4+CD25-) T cells in the periphery can acquire the ex-
pression of FOXP3 and CD25, as well as regulatory T cell activity 
(83–86). 
 The transcription factor FOXP3 is a key component in the 
suppressive function, development, and cell lineage commitment 
of regulatory T cells (56–58). Mutations in FOXP3 may lead to dys-
function of or a lack of Tregs. If this occurs in humans, the condi-
tion called immune dysregulation, polyendocrinopathy, enteropa-
thy, X-linked (IPEX) syndrome may arise, which includes 
uncontrolled cytokine production and proliferation (87,88). How-
ever, recent evidence suggests that there are three isoforms of 
human FOXP3. These three isoforms are full length FOXP3 and 
the two truncated splice forms: FOXP3Δ2, which lacks exon 2, and 
FOXP3Δ2Δ7, which lacks exons 2 and 7 (89–91). It is not known 
whether these FOXP3 isoforms are co-expressed or are expressed 
in different Tregs, but it is conceivable that all three isoforms are 
functionally different. Full length FOXP3 functions as a repressor 
of NF-kB, NF-AT, RORγt and ROR-α (92–96). However, FOXP3Δ2 
isoform is unable to functionally repress RORγt (95), ROR-α (94), 
and NF-kB (96,97). 
 
Th17 and Treg plasticity  
Human Th17 cells are potentially not locked into one pheno-
type but are able to exhibit plasticity.  Annunziato et al were 
among the first to show that a proportion of human Th17 cells 
were able to produce both IL-17 and IFN-γ; they are called the 
‘Th17/Th1 cells’. In the same study, they also showed that human 
Th17 cells were able to differentiate into Th1-like cells and pro-
duce IFN-γ in the presence of IL-12 (98). These cells were called 
‘non-classical Th1’ or ‘Th17-derived Th1 cells’. The expression of 
the IL-12 receptor is important for the differentiation into Th1 
cells (98,99). Additionally, depending on the stimulation Th17 
cells can produce IFN-γ or IL-10. Zielinski et al showed that stimu-
lating with Candida albicans Th17 cells were able to produce IL-17 
and IFN-γ, while stimulating with Staphylococcus aureus, Th17 
cells were able to produce IL-17 and IL-10 (100).  
 In addition to Th17 cells having the ability to exhibit plastic-
ity, there is a growing notion that Tregs can also exhibit plasticity. 
It has been demonstrated that CD4+CD25hi Tregs can express the 
transcription factors FOXP3 and RORγt, concurrently (101,102). 
These CD4+CD25hiFOXP3+ Tregs have also been shown to pro-
duce IL-17 after PMA/ionomycin stimulation with or without IL-1β 
and IL-6 present (101–104). The presence of pro-inflammatory cy-
tokines, such as IL-1β and IL-6, might enhance IL-17 production in 
FOXP3+ Tregs. This might be important at sites of inflammation or 
in autoimmune diseases where these pro-inflammatory cytokines 
are in abundance. However, there are conflicting results as to 
whether or not these IL-17+FOXP3+ Tregs lose their suppressive 
function after secreting IL-17. Voo et al demonstrated that IL-
17+FOXP3+ Tregs are still capable of inhibiting proliferation of 
CD4+ T cells, whereas Beriou et al observed a diminished suppres-
sive activity of IL-17+FOXP3+ Tregs in terms of inhibiting IFN-γ 
production (103,104). A closer and more complex relationship be-
tween CD4+CD25hi Tregs and Th17 cells could exist than initially 
thought.  
 
Human B lymphocytes 
Human B cells are developed in the bone marrow from hema-
topoietic stem cells (105) and have multiple functions within the 
immune system. They are able to produce antibodies, cytokines, 
and function as antigen presenting cells (106–109). B cell subsets, 
such as B1 B cells, transitional B cells, marginal zone B cells, and 
follicular B cells, have been more extensively investigated in mice 
than humans. Therefore, what is currently known about B cell 
subsets in mice and humans is summarized below.  
 
B1 B cells  
In mice, B1 B cells are located in the peritoneal and pleural 
cavities (110,111) and are able to spontaneously produce natural 
antibodies that provide the first line of defense against pathogens 
(14,112,113). Additionally, these B1 B cells are self-replenishing 
(110,114) and are able to efficiently present antigens and induce 
differentiation of effector CD4+ T cells (115). In mice, B1 B cells 
are comprised of two subsets, B1a and B1b, and these subsets are 
defined on the basis of CD5 expression (105,110,114). Similarly, in 
humans, CD5+ B cells play a protective role in the host by the pro-
duction of natural antibodies (116,117). In several autoimmune 
diseases, such as RA and systemic lupus erythematosus (SLE), it 
has been observed that patients have an increased frequency of 
CD5+ B cells and that these B cells are able to produce autoanti-
bodies (118–120). However, the existence of B1 B cells and use of 
CD5 as a phenotypic marker in humans is still under great debate. 
CD5 is expressed on the majority of B cells during childhood as 
well as being used a pan-T cell marker (121,122). It has also been 
speculated that CD5 is an activation marker and that the expres-
sion of CD5 can be induced or upregulated after stimulation with 
phorbol esters - making it unsuitable for the identification of a 
distinct cellular subset (116,123). It has been proposed that the 
human B1 subset can be identified by the phenotype 
CD19+CD27+CD43+ instead of CD5+ (124). Similar to their murine 
counterparts, these human B1 B cells are able to spontaneously 
produce IgM as well as induce stimulation of T cells (124).  
 
Transitional B cells  
The term transitional B cells was first coined in mouse studies 
by Carsetti et al (125) and describes B cells that are developmen-
tally situated between immature B cells in the bone marrow and 
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fully mature B cells in the peripheral blood (126). In mice, transi-
tional B cells have been divided into 
IgMhiCD21negCD23negIgDneg transitional 1 (T1) or 
IgMhiCD21hiCD23hiIgDhi transitional 2 (T2) B cells (122,127). The 
expression of the developmental marker, CD23, highlights the dif-
ference in the development between the two subsets (128). 
These CD23hi T2 subsets are located primarily in the spleen and 
are more capable than T1 B cells in terms of proliferating, differ-
entiating and surviving BCR-induced activation, thus allowing for 
development into mature B cells (128–131). T1 B cells are located 
in the bone marrow, blood and spleen and readily die via apopto-
sis after BCR-induced activation. It has also been suggested that 
T1 B cells are the precursors for T2 B cells. However, T1 B cells 
may also develop directly into mature B cells (130).   
 In humans, earlier observations characterized transitional B 
cells, located in the peripheral blood or bone marrow, as 
CD19+CD24hiCD38hi using the two developmental markers CD24 
and CD38 (122,131). Additionally, studies have shown that the 
human bone marrow has a greater proportion of B cells express-
ing the CD24hiCD38hi transitional phenotype, and that these 
transitional B cells were able to reconstitute the peripheral blood 
after hematopoietic stem cell transplantation (126,132). How-
ever, more recent studies have indicated that humans, like mice, 
have two subsets of transitional B cells, namely T1 and T2 
(133,134). Human T1 and T2 transitional B cells have been subdi-
vided based on the low or high expression of CD21 or IgD 
(126,134). The difference in the expression of CD21 or IgD may in-
dicate a difference in the developmental stage of the transitional 
B cells (126,134). Similar to CD23 in mice, CD21hi T2 B cells in hu-
mans are better at proliferating and secreting immunoglobulins 
than CD21low T1 B cells, indicating that T2 B cells are more devel-
opmentally mature than T1 B cells (134). Additionally, human T1 
B cells are more prone to apoptosis than T2 B cells, which is com-
parable to their murine counterpart (131).  
 
Marginal zone and Follicular B cells    
Marginal zone (MZ) and follicular zone (FO) B cells are two 
subsets of the splenic B cell subset (135), which may be derived 
from transitional T2 B cells (136). MZ B cells are located in the 
marginal zone of the spleen whereas FO B cells are primarily lo-
cated in the lymphoid follicles of the secondary lymphoid organs 
(111,136,137). In mice, the phenotype for MZ B cells is IgMhiIgD-
lowCD21hiCD23low whereas for FO B cells it is 
IgMlowIgDhiCD21intCD23hi (138). FO B cells are able to circulate, 
capture and present T cell-dependent antigens to CD4+ T cells 
present in the lymphoid follicles in the white pulp (111,136). Ad-
ditionally, FO B cells may have a role in the production of IgM an-
tibodies in a T cell-independent manner in the bone marrow. This 
indicates that FO B cells may reside in both the spleen and bone 
marrow and carry out different functions (111,136,139). MZ B 
cells are able to rapidly produce antibodies against T cell-inde-
pendent antigens, such as bacterial antigens, making these cells 
crucial as the first line of defense against blood-borne pathogens 
(14,137). In a similar way to FO B cells, studies have shown that 
MZ B cells can capture and present T cell-dependent antigens to 
CD4+ T cells and induce antigen-specific differentiation and prolif-
eration (111,138,140). It has been proposed that MZ B cells are 
more capable of presenting antigens to T cells than FO B cells due 
to their high expression of co-stimulatory molecules 
(111,138,140). Another important function of MZ B cells is the 
shuttling of antigens from the marginal zone to the lymphoid folli-
cles in the spleen. MZ B cells were initially thought of as being 
sessile however, a study by Cinamon et al demonstrated that MZ 
B cells are able to pick up antigen and transport it to the follicles 
in the spleen (141,142). In humans, MZ B cells have been found 
and may exhibit similar functions as their murine counterparts. 
There is evidence that human MZ B cells  are important in pro-
cessing and presenting T cell-independent antigens and providing 
first line of defense (143). Tables 1 summarizes the different B cell 
phenotypes discussed in this thesis, and are associated with B1 B 
cells, transitional B cells, MZ, and FO B cells as well as regulatory B 
cells.  
 
Table 1 Summary of B cell phenotypes associated with different B cell 
subsets. 
 
 
Regulatory B cells 
It has long been believed that B cells may have a suppressive 
capacity. In the murine model for multiple sclerosis, namely ex-
perimental autoimmune encephalomyelitis (EAE), Wolf et al have 
demonstrated that mice deficient in B cells due to a genetic fault 
have a greater degree of disease severity and suffer from chronic 
EAE (144). What role these B cells play in the pathogenesis of EAE 
was unclear until Fillatreau et al demonstrated that murine B cells 
were capable of producing IL-10. It was precisely the production 
of IL-10 that suppressed the Th1-type/pro-inflammatory re-
sponses and allowed the EAE mice to recover, proving that B cells 
did have a regulatory function (11,145). A regulatory role for B 
cells and IL-10 has subsequently been demonstrated in other mu-
rine models of intestinal inflammation (146,147) and autoimmun-
ity including collagen-induced arthritis, a model for RA (148,149). 
In murine studies, IL-10 produced by murine B cells are able to 
suppress Th1 and Th17 cells, thereby reducing the production of 
pro-inflammatory cytokines and responses (147–149). In a study 
by Carter et al, IL-10-producing B cells were actually capable of in-
ducing iTregs (149). 
 The existence of regulatory B cells (Bregs) has also been 
demonstrated in humans. In some studies, Bregs may also be 
called B10 cells; however, these B10 cells normally denote IL-10-
producing B cells. Currently, no one particular surface marker or 
transcription factor has been pin-pointed to identify Bregs. There-
fore, the ability to produce IL-10 is the best marker to date. Sev-
eral phenotypes have been proposed to identify Bregs, but cur-
rently there is no consensus. Some of the prevailing phenotypes 
include CD5+, CD25hi, TIM-1+, CD27+CD43+, 
CD27+CD43+CD11b+, CD24hiCD27+, and CD24hiCD38hi 
(121,124,150–161). A suppressive quality, in terms of inhibiting 
cytokine production, proliferation or differentiation, has also 
been demonstrated in human Bregs. Human CD24hiCD27+ Bregs 
have the ability to inhibit pro-inflammatory cytokine production 
such as TNF-α and IFN-γ from monocytes and CD4+ T cells, re-
spectively, in an IL-10-dependent manner (154,156). Predomi-
nately human B10 cells with the phenotypes CD25hi, TIM-1+, 
CD24hiCD27+ and CD24hiCD38hi, have been shown to suppress 
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CD4+ T cell activation or proliferation as well as inhibit differentia-
tion of naïve CD4+ T cells into Th1 or Th17 cells 
(151,157,158,161,162).  
 Additionally, a number of phenotypic subpopulations such as 
CD24hiCD27+ and CD24hiCD38hi have been able to convert effec-
tor (CD4+CD25-) T cells into Tregs (CD4+CD25hi) with an intact 
functional suppressive capacity (158–160). Kessel et al demon-
strated that CD19+CD25hi Bregs were able to enhance the ex-
pression of FOXP3 and CTLA-4 in Tregs. However, this was not de-
pendent on IL-10 but instead partially dependent on TGF-β and 
cell-to-cell contact (157). Intriguingly, Bregs have also been shown 
to inhibit TNF-α production from CD4+ T cells via an IL-10-inde-
pendent pathway (156). This contributes to the theory or specula-
tion that Bregs may induce suppression via cytokine-independent 
methods.  
 In summary, this indicates that B10 cells may have multiple 
phenotypes and may have an array of suppressive activities. Cur-
rently, there is no definitive B10 cell phenotype (see appendix I 
for a table reviewing some of the current Breg/B10 literature).  
 
Autoimmune thyroid disease 
Autoimmune thyroid disease (AITD), which encompasses 
Hashimoto’s thyroiditis (HT) and Graves’ disease (GD), are classi-
cal examples of organ-specific autoimmunity (2). These two dis-
eases are clinically diverse because GD is primarily a humoral dis-
ease where autoantibodies are generated against the thyroid 
stimulating hormone receptor (TSHR) leading to hyperthyroidism, 
whereas in HT, T cells aid in the destruction of the thyroid epithe-
lial cells (thyrocytes) and thyroid epithelial structure leading to 
hypothyroidism (2,163–165). However, these diseases still share 
several immunological features. These features include lympho-
cytic infiltration of the thyroid gland as well as auto-reactivity 
against three thyroid auto-antigens which are thyroglobulin (TG), 
thyroid perioxidase (TPO) and TSHR (166,167). Figure 3 outlines 
the immuno-pathogenesis of HT and GD.  
 
Clinical diagnosis of GD and HT patients 
Diagnosing GD or HT is dependent on measuring the levels of 
thyroid stimulating hormone (TSH), serum freeT4 (FT4) and 
freeT3 (FT3) as well as measuring the autoantibody levels against 
TSHR and TPO.  Individuals diagnosed with GD have suppressed 
levels of TSH with elevated levels of FT4 and/or FT3 along with el-
evated anti-TSHR antibody levels. An ultrasound of the thyroid 
demonstrating diffuse hypoecchogenicity can be used to confirm 
the GD diagnosis (168). The presence of suppressed TSH, but nor-
mal FT4 or FT3 may indicate subclinical hyperthyroidism (169). In 
contrast to GD, HT patients have a raised TSH level, a decreased 
level of FT4 or FT3 and the presence of anti-TPO Ab and/or anti-
TG Ab (165,170). If HT patients have a raised serum TSH level, but 
normal FT4 level, that indicates subclinical hypothyroidism (165).  
Approximately 95% of all HT patients have anti-TPO antibodies 
and about 60-80% of HT patients have anti-TG antibodies 
(170). The presence of anti-TPO Abs is a clinical marker for HT, 
while anti-TSHR Ab is a clinical marker for GD (170,171). However, 
anti-TPO Abs and anti-TG Abs are not unique to HT patients be-
cause these antibodies are detectable in the majority of GD pa-
tients (168).  
 
Epidemiology, genetic and environmental factors of GD and HT 
patients 
Both GD and HT are among the most common autoimmune 
diseases (168,170). Approximately, 2% of the general population 
will develop either GD or HT (172,173). In Denmark, the preva-
lence of female HT patients was 0.4% (174) whereas the preva-
lence for female GD patients was 1.2% (175) These diseases have 
a strong female preponderance, which could in part be due to the 
hormone estrogen (164,176). Parity, the number of times a 
women has given birth, and skewed X-chromosome inactivation 
can help to explain the predominance of GD or HT in females 
(176,177). 
GD and HT are complex diseases caused by a combination of 
genetic and environmental factors (173,174,178,179). Few sus-
ceptibility genes have been discovered and can roughly be divided 
into immuno-regulatory (HLA-DR, CTLA4, CD40, PTPN22, CD25, 
and FOXP3) and thyroid-specific genes (TSHR and TG) 
(164,168,171,176,180,181). However, not all of these susceptibil-
ity genes are a causative factor for both GD and HT development 
because the susceptibility genes CD25, CD40 and TSHR are spe-
cific only for GD patients (181). The environmental factors such as 
dietary iodine, stress, smoking, and alcohol have all been associ-
ated with autoimmune thyroid disease (176). Stress or having a 
stressful daily life may be a risk factor for developing GD, but sur-
prisingly, not for the development of HT (176). In Denmark, iodine 
was added to table salt and bread in order to prevent country-
wide iodine deficiency. As a result of iodine fortification in Den-
mark, the incidence of hypothyroidism increased, but the preva-
lence of hyperthyroidism remained the same (182–185). It has 
been speculated that smoking is associated with the development 
of AITD (186). Studies from Denmark have shown that cigarette 
smoking has a protective effect for development of HT/hypothy-
roidism, but is a risk factor for GD development (173,187,188). 
Surprisingly, Danish population-based case-control studies have 
revealed that alcohol may have a protective effect and prevent 
the development of GD and HT (189,190). However, the mecha-
nisms by which these environmental factors drive AITD pathogen-
esis is still not clear.  
 
Graves’ disease 
As mentioned earlier, GD is an autoantibody-mediated dis-
ease and often, but not always, is lymphocytic infiltration present 
in GD patients (167,191). However, the lymphocytic infiltration 
detected in GD patients may not be as severe as HT or destroy the 
thyroid architecture (192). In GD, the lymphocytic infiltrate con-
sists mainly of CD4+ and CD8+ T cells as well as CD19+ B cells. As a 
result of this lymphocytic infiltration into the thyroid gland, ec-
topic germinal centers (GC) can be formed (191,193). These ec-
topic GC are secondary lymphoid follicles, which contain autore-
active B cells and allows the affinity maturation of autoreactive B 
cells. This can potentially lead to the production of autoantibodies 
(2,194,195). GC might be the source of autoantibodies in the 
pathogenesis of GD as well as HT.   
It is a well-known fact that pathognomonic antibodies are 
produced against the TSHR in GD, which leads to the over-activa-
tion of the thyroid gland and hyperthyroidism (168,196). These 
TSHR autoantibodies, also called TRAb, primarily belong to the 
immunoglobulin (Ig) G subtype (197). The types of  TSHR auto-an-
tibodies includes thyroid stimulatory (TSAb), TSH blocking (TBAb) 
and neutral auto-antibodies, which all are regarded to have dif-
ferent biological activity (196,198–200). For example, TSAb will 
bind and stimulate the TSHR, which induces proliferation as well 
as increases the thyroid hormone production and consequently 
leads to hyperthyroidism. Conversely, TBAb, will lead to hypothy-
roidism because these autoantibodies block the TSHR and reduce 
thyroid hormone production (198,199,201). The exact function of 
the neutral TSHR autoantibodies is not yet clear since it seems to 
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neither stimulate nor block the TSHR (196). The TSHR belongs to 
the G-protein coupled receptor family and is made up of an ecto-
domain subunit A and a transmembrane subunit B (164,201). 
Uniquely to the TSHR, this receptor undergoes intramolecular 
cleavage in the ectodomain resulting in the shedding of the subu-
nit A (196,201). It has been suggested that the ‘free or shed’ sub-
unit A is the immunogen that induces the production of TSHR au-
toantibodies by B cells (163,202,203). This is because recent 
studies have shown that monoclonal TSHR Abs of both human 
and murine origin have a higher affinity towards the ‘free or shed’ 
subunit A rather than the holoreceptor (202,203).  
Human CD4+ T cells may have several roles within GD patho-
genesis. Firstly, the interaction between CD4+ T cells and auto-re-
active B cells is required for the production of autoantibodies 
against the TSHR (2,107,108,164,200). Secondly, CD4+ T cells pro-
duce cytokines, predominately Th2-related, including IL-4, IL-5 
and IL-10, which may play a protective role in GD (192,204–206). 
Production of IL-4 and IL-10 may prevent thyrocyte destruction by 
inducing T cell anergy, preventing IFN-γ production by macro-
phages, inhibiting cytotoxic responses from CD8+ T cells, and by 
inducing a phenotypic switch from Th1 to Th2 (2,207,208). IL-4 
and IL-10 may also up-regulate the expression of anti-apoptotic 
proteins from the BCL-2 family, which includes Bcl-2, Bcl-xL, and 
cFLIP (192). Expression of these anti-apoptotic proteins in thyro-
cytes hinders the activation of the caspase pathway which in-
duces apoptosis (2,209).  
 
 
Figure 3. The immune-pathogenesis of Hashimoto thyroiditis and Graves’ 
disease (Reprinted by permission from Macmillan Publishers Ltd: [Nat Rev 
Immunol] (Stassi and De Maria; 2:195–204), copyright (2002) (2)).  
 
Hashimoto’s thyroiditis 
Hashimoto’s thyroiditis (HT) is primarily a T-cell mediated dis-
ease where the thyroid parenchyma is destroyed (210). The hu-
man thyroid gland is infiltrated with CD4+ and CD8+ T cells, 
CD19+ B cells, macrophages, and plasma cells leading to destruc-
tion of the thyrocytes, fibrosis, impaired thyroid hormone produc-
tion and eventually hypothyroidism (2,166,192,210). However, 
what the initial insult is that causes the lymphocytic infiltration 
into the human thyroid gland is still unclear.  
B cells may play multiple roles within HT pathogenesis. Pri-
marily, auto-reactive B cells in HT could be the predominant 
source for autoantibodies against TG and TPO. These autoanti-
bodies can be produced in various locations including ectopic ger-
minal centers (194,195,210). Additionally, B cells may act as the 
antigen presenting cell, presenting thyroid self-antigens and thus 
activating naïve auto-reactive CD4+ T cells (8,165). B cells, which 
also have the ability to produce cytokines, may be a source for cy-
tokines contributing to inflammation (211,212). However, the ex-
act role of B cells in HT pathogenesis remains unclear.   
Primarily, HT is characterized by thyrocyte destruction, and 
the rate at which thyrocytes are destroyed determines the clinical 
outcome of the disease (2,213). Thyrocyte destruction can occur 
via three main mechanisms: cytotoxic T lymphocytes, death re-
ceptors, and antibodies (2).  
The role of T cells in HT pathogenesis is well-established. A 
murine study by Flynn et al showed that L3T4 (mouse CD4+ T 
cells) are responsible for the initiation of experimental autoim-
mune thyroiditis (EAT). In the same study, Flynn et al showed that 
Lyt-2+ cells (mouse CD8+ T cells) played a cytotoxic role in EAT 
pathogenesis (214). The present theory is that auto-reactive CD4+ 
T cells become activated, which induces the migration of both B 
cells and cytotoxic CD8+ T cells into the thyroid gland (166,215). 
Cytotoxic T lymphocytes (CTLs) produce cytotoxic granules such 
as perforin, granzymes (including granzyme B), and proteoglycans 
(216). The perforin molecule functions by forming a pore in the 
cellular membrane of target cells, and granzyme B functions by 
activating pro-apoptotic molecules such as caspases and cyto-
chrome c (2). The presence of CTLs or perforin-secreting intra-thy-
roidal T cells has been detected among HT patients and could be 
one of the causative factors for thyrocyte destruction and hypo-
thyroidism (217,218). A study by Ehlers et al demonstrated that 
TPO- and TG-specific CD8+ T cells are present in the peripheral 
blood and in the thyroid gland of HT patients. The study further 
demonstrates that these TPO- and TG-specific CD8+ T cells were 
able to cause the lysis of target cells in vitro. Given the cytotoxic 
ability of these TPO- and TG-specific CD8+ T cells, this could be an 
important mechanism for thyrocyte destruction in HT (219). Addi-
tionally, the presence of IFN-γ in the local environment may be 
able to promote the expression of several pro-apoptotic genes as 
well as increase the activity of caspases 3 and 8 and thus perpetu-
ate thyrocyte destruction (2,209).  
The second mechanism for thyrocyte destruction is via death 
receptors.  Death receptors including FAS (CD95) have a cytoplas-
mic death domain that allows the transmission of the apoptotic 
signal into the cell (220). There is evidence that thyrocytes from 
HT patients have the expression of both FAS and FAS ligand 
(213,221–223). A theory is proposed that thyrocytes from HT pa-
tients undergo thyrocyte apototosis in a suicide or fraticide de-
pendent manner due to the simultaneous expression of FAS and 
FAS ligand (2,215,221,224). This theory is proposed to be one of 
the main mechanisms for thyrocyte destruction. The interaction 
between FAS and FAS ligand will induce apoptotsis in the cell car-
rying FAS. Activation of a cell death receptor also enhances the 
expression of pro-apoptotic genes such as Bid and Bak, which en-
courages apoptosis in the thyrocyte (192).  
It has been suggested that the pro-inflammatory cytokines 
IFN-γ and IL-1β, are able to enhance the expression of FAS on hu-
man thyrocytes, especially in HT patients (192,213,215,221–
223,225). It has been theorized that the presence of IFN-γ and IL-
1β in the thyroid gland of HT patients may induce or upregulate 
the expression of FAS.  This increased FAS expression may perpet-
uate thyrocyte destruction (222). Evidence has shown that infil-
trating T cells among HT patients had low or lacked any significant 
expression of FAS ligand indicating that infiltrating T cells did not 
induce thyrocyte destruction (215,222,224,226). However, infil-
trating T cells still might play a role in thyrocyte destruction by 
providing the cytokines IL-1β and IFN-γ (222). 
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The third mechanism of thyrocyte destruction is by autoanti-
bodies. Characteristically, patients with HT have autoantibodies 
against TG and/or TPO (210). Several studies have shown that au-
toantibodies, especially IgG1 anti-TPO antibodies, may cause thy-
rocyte destruction by fixing complement and inducing antibody-
dependent cell-mediated cytotoxicity (ADCC) (227,228). As a re-
sult, the destroyed thyrocytes will then release cytokines such as 
IL-6, IL-1β, and IL-8, which can either initiate or perpetuate the in-
flammation by causing more lymphocytes to migrate to the thy-
roid gland (2,229,230). Our group has shown that TPO-antibodies 
promote production of pro-inflammatory cytokines by phagocytic 
cells and T cells, by facilitating binding of TPO/anti-TPO complexes 
to Fcγ-receptors on antigen-presenting cells (231). However, un-
certainty remains as to whether autoantibodies are truly patho-
genic or are secondary to the inflammation and destruction oc-
curring in the thyroid gland (232).  
It was initially believed that HT was a Th1-mediated disease, 
and there is ample of evidence to support this theory (233–236). 
However, recent data is suggesting that Th17 cells may play a 
more prominent role in HT. In particular, studies by Shi et al, 
Nanba et al and Figueroa-Vega et al, have shown that HT patients 
have increased proportions of circulating Th17 cells secreting IL-
17, both in the peripheral blood and thyroid gland (39–41). IL-17 
is known to be pro-inflammatory and induce the production of 
other pro-inflammatory cytokines such as IL-1β and IL-6, both of 
which have a role in HT, and chemokines from neighboring cells 
(35). Thus, this might perpetuate the inflammation and enhance 
the migration of lymphocytes into the thyroid gland. IFN-γ, which 
has a critical role in HT, is a key cytokine for Th1 cells. However, 
IFN-γ may also be produced by Th17 cells. There is data to suggest 
that Th17 cells are able to produce both IL-17 and IFN-γ (called 
Th17/Th1 cells) (98). Additionally, in sites with chronic inflamma-
tion, Th17 cells may differentiate into Th1 cells if IL-12 is present 
(99). Further investigations are needed to determine which Th 
subset, Th1, Th17 or Th17/Th1, is more important in HT. 
 
Role of thyroid epithelial cells in AITD 
Thyroid epithelial cells or thyrocytes may have a much larger 
role to play in the pathogenesis of HT and GD than initially 
thought. Thyrocytes have been shown to express MHC class II 
which interacts with CD4+ T cells (237). The expression of MHC 
class II, induced by IFN-γ, allows the thyrocyte to act as an antigen 
presenting cell (237,238).  Under normal conditions, the MHC 
class II expression induces anergy in naïve CD4+ T cells due to the 
lack of the co-stimulatory molecules CD80/CD86 on the thyrocyte. 
Therefore, under normal conditions, thyrocytes are able to induce 
peripheral tolerance (180,239).  However, in AITD, auto-reactive 
memory CD4+ T cells exist and become stimulated and proliferate 
in response to the auto-antigens presented by MHC class II on the 
thyrocyte. This will then perpetuate the autoimmune response 
(180,237). Additionally, thyrocytes, themselves, are able to pro-
duce and secrete a whole host of pro-inflammatory cytokines and 
chemokines. These cytokines and chemokine will stimulate T cells 
and B cells and increase the migration of lymphocytes to the thy-
roid gland, thus perpetuating the disease (229,230,240,241). 
Therefore, thyrocytes may not be the innocent bystander, as once 
believed, and may, in fact, play an important role in the patho-
genesis of AITD.  
 
Aims of the PhD study  
The overall aim of this PhD study is to investigate the patho-
genesis of autoimmune thyroid disease with respect to thyroid 
self-antigens and the effect they have on the immune system.  
 
The specific objectives of this PhD study are:  
 To investigate the ability of B cells to present AITD-associ-
ated self-antigens including TG and TPO to T cells in healthy 
donors and AITD patients.  
 To determine whether TG and/or TPO could drive a pro-in-
flammatory or regulatory response in B cells and CD4+ T cells 
in healthy donors and AITD patients.  
 To investigate if there is a difference between healthy do-
nors and AITD patients with respect to B cell phenotypes as-
sociated with regulatory B cells.   
 To investigate whether the regulatory response is impaired 
or defective in patients with AITD in comparison to healthy 
donors.  
 
Summary of papers I to III 
A summary of the findings from all three articles are outlined 
below.  
 
Paper I: B-cell exposure to self-antigen induces IL-10 produc-
ing B cells as well as IL-6- and TNF-α-producing B-cell subsets in 
healthy humans.  
Material and Methods: Peripheral blood mononuclear cells 
(PBMC) were isolated from 18 healthy donors. Monocytes or B 
cells were depleted from isolated PBMC using Dynabeads coated 
with anti-CD14 or anti-CD19, respectively, followed by CFSE label-
ling. CFSE-labelled intact PBMC or monocyte-/B-cell-depleted 
PBMC were plated at a density of 2.5 x 105 cells per well in a 96-
well plate and stimulated with TG (30µg/mL) or TT (30µg/mL) for 
7 days. Culture supernatants were collected at day 1 and the cy-
tokines measured were TNF-α, IFN-γ, IL-2, IL-4, IL-6, and IL-10 us-
ing the Th1/Th2 cytometric bead array kit. Concomitantly, B cells 
and CD3+ T cells were purified from intact PBMC using Human B 
cell Enrichment and Human CD3 Positive selection kits, respec-
tively. Purified B cells were preloaded with no antigen, TG 
(30µg/mL) or TT (30µg/mL). 1.0 x 105 TG- or TT-pulsed B cells 
were co-cultured with 2.5 x 105 purified CD3+ T cells for either 
overnight or 7 days. The cytokines TNF-α and IL-10 were meas-
ured using anti-CD45/anti-capture antibody beads, whereas IL-6 
was detected using intracellular staining and stained with anti-IL-
6 PE antibody.   
Results: Depletion of monocytes from intact PBMC induced a 
significant reduction in TNF-α, IL-6 and IL-10 production (P<0.009, 
P<0.02, P<0.04 respectively). However, depletion of B cells re-
sulted in a significant reduction of IL-10 only (P<0.05). TG-pulsed 
B cells, but not TT-pulsed B cells, were able to induce IL-10 secre-
tion in 1.1 ± 0.5% of B cells (P=0.01 versus TT) and 1.0 ± 0.2% of 
CD4+ T cells (P=0.006 versus TT). Additionally, TG also induced se-
cretion of IL-6 and TGF-β. In contrast, TT induced secretion of the 
Th1-type cytokines IFN-γ and IL-2. Both TG- and TT-pulsed B cells 
induced TNF-α secretion. The IL-10-secreting B cells detected in 
this study were significantly enriched with the surface markers 
CD5 (P=0.03 versus non-IL-10 secreting cells) and CD24 (P=0.02 
versus non-IL-10 secreting cells), and not with CD27 and CD38 
surface markers. After 7 days, IL-10 secretion by 3.3 ± 1.0% of 
CD4+ T cells was still observable after co-culture with TG-pulsed B 
cells. No IL-10 secretion was detected from TG-pulsed B cells on 
day 7.   
Conclusions:  Our findings show that B cells pulsed with the 
self-antigen TG is able to induce the secretion of IL-10 in both B 
cells and CD4+ T cells. Additionally, TG-pulsed B cells also induced 
the production of IL-6 and TNF-α. Also, higher frequencies of the 
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IL-10-secreting B cells were CD5+ and CD24hi. Together, TG-
pulsed B cells are able to drive a protective immune response.  
 
Paper II: Characterization of Regulatory B cells in Graves’ 
Disease and Hashimoto’s Thyroiditis. 
Material and Methods: Peripheral blood was collected from 
12 healthy donors as well as from 12 HT patients and 12 GD pa-
tients. For induction of cytokine production, 1 x 106 isolated in-
tact PBMC were stimulated with phorbol 12-myristate 13-acetate 
(PMA) and ionomycin cell stimulation cocktail (2µL/well) for 4 h. 
PBMC were stained extracellularly with a combination of the fol-
lowing antibodies: anti-CD19-PerCP, anti-CD5 APC, anti-CD43 
FITC, anti-CD27 PECy7, anti-CD24 FITC, anti-CD38 PECy7, anti-
CD25 FITC, anti-TIM-1 PE, and intracellularly with either anti-IL-10 
APC or anti-IL-10 PE. Concurrently, B cells were isolated and puri-
fied using the Human CD19 Positive Cell Isolation kit. Purified B 
cells (1 x 105 cells) were preloaded with TG (30 μg/mL) or CpG oli-
godeoxynucleotide (ODN; 10 µg/mL) for one hour. The preloaded 
B cells were co-cultured with 2 x 105 of the remaining PBMC for 
48 h.  The co-cultured cells were stained extracellularly and intra-
cellularly with anti-CD19 APC, anti-CD14 FITC, anti-CD4 PerCP, 
anti-CD8 PECy7, and anti-IL-10 PE. 
Results: Among the HT patients, 6.1% and 2.5% of the bulk B 
cells expressed the surface markers CD25 and TIM-1, respectively, 
in comparison to 2.9% and 1.6% of the bulk B cells among the 
healthy donors (P=0.026 and P=0.015 respectively). GD patients 
did not differ in their frequency of CD25+ or TIM-1+ B cells when 
compared to healthy donors. No differences were found between 
each patient group and healthy donors in terms of CD24hiCD38hi 
and CD27+CD43+ B cells frequencies. However, patients with HT 
or GD had a lower frequency of CD24hiCD38- B cells than healthy 
donors (P=0.02 and P=0.0005, respectively). Additionally, GD pa-
tients also had lower proportions of CD27+CD43- B cells (P=0.037 
versus healthy donors). The cytokine IL-10 was induced by the 
polyclonal stimuli PMA/ionomycin and CpG ODN and by the anti-
gen-specific stimulus TG. PMA/ionomycin and CpG ODN induced 
IL-10 secretion from approximately 1% of B cells. TG induced IL-10 
secretion in 0.05% of healthy donor and HT patient B cells as well 
as in 0.18% of GD patient B cells. No differences were detected in 
the frequency of IL-10-secreting cells between each patient group 
and healthy donors after stimulation with PMA/ionomycin, CpG 
ODN or TG. HT patients had a significantly higher proportion of 
CD25+ and TIM-1+ B10 cells than healthy donors (P=0.0009 in 
both cases). Similarly, GD patients also had a significantly higher 
proportion of CD25+ and TIM-1+ B10 cells than healthy controls 
(P=0.039 and P=0.024, respectively). Similarly to bulk B cells, no 
differences were found in the proportions of CD24hiCD38hi and 
CD27+CD43+ B10 cells between patients and healthy donors. HT 
patients had a significantly lower proportion of B10 cells within 
the CD24hiCD38- subset than healthy donors (P=0.012).  GD pa-
tients had a lower proportion of CD27+CD43- B10 cells than 
healthy donors (P=0.019).  
Conclusions: Similar frequency of B10 cells are detected in HT, 
GD and healthy donors indicating that B cells from patients are 
not impaired with respect to inducing an immuno-regulatory re-
sponse. The B10 cells did not segregate into any clearly defined 
subgroups, but HT patients had increased frequencies of CD25+ 
and TIM-1+ B10 cells.   
 
Paper III: Altered balance between self-reactive Th17 cells 
and Th10 cells and between full-length FOXP3 and FOXP3 splice 
variants in Hashimoto’s thyroiditis. 
Material and Methods: This study included blood from 10 HT 
patients, 11 GD patients and 15 healthy donors. Isolated PBMC 
were plated onto a 96-well plate with a density of 5 x 105 cells 
per well and stimulated with either TG (30µg/mL), TPO 
(30µg/mL), E. coli LPS (50ng/mL), anti-CD3/anti-CD28 or left un-
stimulated. PBMC were stimulated for a total of 18h to measure 
IL-17 or IL-6 or for 48h to measure IL-10. PBMC were first extra-
cellularly stained with anti-CD4 PerCP, anti-CD45RA FITC, and 
anti-CD45R0 APC, and then intracellularly stained for either anti-
IL-17A PE, anti-IL-6 PE or anti-IL-10 PE. Culture supernatants were 
assessed for IL-1β, IL-6, and TGF-β1 production by Luminex after 
18h. Concurrently, mRNA was extracted, purified and cDNA was 
synthesized from 5 x 105 PBMC after no stimulation or stimula-
tion with TG, TPO, E. coli LPS or anti-CD3/anti-CD28. Subse-
quently, total FOXP3 and FOXP3Δ2 isoform was measured. As 
house-keeping gene, CD4 was utilized due to the stability of its 
expression irrespective of stimulation or not. Additionally, FOXP3 
is expressed by CD4, thus it is preferred to use a house-keeping 
gene that is specific to the cell population studied. 
Results: After stimulating with the thyroid self-antigen TG, no 
differences in the frequency of IL-17 producing cells were de-
tected between each patient group and healthy donors in either 
the naïve or memory Th cell compartments. In contrast, TPO and 
E. coli LPS induced IL-17 production in 2.8 and 11.9 per 10,000 na-
ïve Th cells among HT patients, but failed to do so in GD patients 
or healthy donors (P=0.016 and P=0.014 versus healthy donors, 
respectively). The induction of Th10 cells, was uniform between 
each patient group and healthy donors, irrespective of whether 
TG, TPO or E. coli LPS was used as a stimulus. However, compared 
to healthy donors, a significant reduction in the proportion of IL-
10-producing cells were observed among HT patients after anti-
CD3/anti-CD28 stimulation (P=0.028). After stimulation with TG, 
naïve Th cells among healthy donors preferentially differentiated 
towards a Th10 phenotype, whereas the naïve Th cells among pa-
tients with HT or GD differentiated towards a Th17 phenotype. HT 
patients had a higher baseline production of both IL-6 and TGF-β1 
than healthy donors (P=0.038 and P=0.0096, respectively) possi-
bly contributing towards Th17 differentiation. Only in the healthy 
donor group did stimulation with TG or TPO enhance the IL-6 pro-
duction above the basal level. In contrast, E. coli LPS induced the 
production of IL-6 above the basal level in all three groups. Stimu-
lation with TG, TPO or E. coli LPS did not alter TGF-β1 expression 
in any of the three groups. In addition, the baseline expression of 
total FOXP3 was uniform in all three groups. However, HT pa-
tients as well as GD patients had a higher baseline expression of 
FOXP3Δ2 than healthy donors (P=0.012 in both cases).    
Conclusions:  An increased frequency of thyroid antigen-spe-
cific Th17 cells in the naïve CD4+ T cell compartment is detected 
in HT patients while the frequency of Th10 cells remains unal-
tered. This indicates a skewed Th17:Th10 ratio in HT patients. Ad-
ditionally, an elevated baseline production of IL-6 and TGF-β1 and 
of mRNA encoding FOXPΔ2 may contribute to the skew towards 
Th17 differentiation detected in HT patients.  
 
Discussion  
The discussion below will deal with IL-10 production by B 
cells, regulatory B cell phenotypes, the antigen presenting ability 
of B cells and monocytes, IL-10 and IL-17 production from CD4+ T 
cells, Th17/Th10 ratio and Th17 differentiation, and finally FOXP3 
and Th17 plasticity.  
 
The B cell studies 
IL-10 production by B cells 
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The human cytokine IL-10 is a regulatory cytokine and was ini-
tially discovered by Mossman and colleagues who showed that 
murine IL-10 was able to inhibit cytokine production from Th1 
cells (242). The biological activities of IL-10 are far-reaching and 
have been shown to have immunosuppressive effects on mono-
cytes and macrophages in terms of inhibiting pro-inflammatory 
cytokine production as well as antigen presentation (74–76,243). 
Opposed to the effects of IL-10 on monocytes and macrophages, 
IL-10 has been shown to have immuno-stimulatory effects on hu-
man B cells. In this case, IL-10 helps to prevent apoptosis, in-
creases proliferation and enhances antigen presentation by B 
cells by up-regulating MHC class II expression (74–76). 
In our B cell studies, we used the polyclonal stimuli 
PMA/ionomycin and CpG ODN 2006 (Toll-like receptor 9 ligand) 
to maximally stimulate the B cells, as well as a more biologically 
relevant stimulus, the thyroid self-antigen thyroglobulin (TG). The 
foreign recall antigen tetanus toxoid (TT) was also used.  
In paper I, TG was found to be able to induce a significant se-
cretion of the anti-inflammatory cytokine IL-10 in human B cells 
from healthy donors. This was in contrast to the foreign recall an-
tigen TT, which induced more Th1-type cytokines such as IFN-γ 
and IL-2, and minimal IL-10. It should be noted that TG also in-
duced the secretion of some pro-inflammatory cytokines includ-
ing IL-6 and TNF-α from B cells in healthy donors. Similarly, in pa-
per II we were able to induce IL-10 secretion after TG stimulation 
in healthy donors and in patients with GD or HT. Notably, TG in-
duced similar proportions of IL-10 in all three donor groups. Using 
TG as the stimulus proved that self-antigens can induce IL-10 se-
cretion from healthy donors and patients. This is novel because 
IL-10 has been predominately induced by polyclonal stimulation, 
and TG is more relevant to the pathogenesis of AITD. This indi-
cates that self-antigens induce antigen-specific immuno-regula-
tory responses by B cells, which may play a role in controlling 
AITD.  Additionally, in paper II, the polyclonal stimuli PMA/iono-
mycin or CpG were used to induce IL-10 secretion. Such polyclo-
nal stimuli are potent and induce the maximum IL-10 secretion by 
B cells. CpG stimulates B cells by interacting with its receptor TLR9 
and activates NF-κB. This is in contrast to PMA/ionomycin, which 
diffuses across the cell membrane and activates protein kinase C 
and NFAT (244–247). We demonstrated that IL-10 secretion was 
similar between each patient group and healthy donors after 
PMA/ionomycin or CpG stimulation. In contrast to our results, Zha 
et al observed a significant decrease in the ability of B cells to se-
crete IL-10 from new-onset GD patients after stimulation with 
CpG and PMA/ionomycin (156). An explanation for this discrep-
ancy could be that Zha et al divided the GD patients into two 
groups based on disease status, active disease and euthyroid, and 
stated that none of the patients were undergoing anti-thyroid 
drug treatment before blood collection (156). The possible effects 
of anti-thyroid drugs on our cytokine production will be discussed 
below, under the limitations section. The observation that pa-
tients with GD or HT were equally as capable of secreting IL-10 as 
the healthy donors, irrespective of whether TG, PMA/ionomycin 
or CpG was used, indicates that GD or HT patients do not have a 
defective immuno-regulation by B cells. 
The main difference between the observed B-cell production 
of IL-10 in paper I and II was the amount of IL-10 secreted after 
TG stimulation. In paper I, we detected IL-10 secretion from 1.00 
± 0.5% healthy donor B cells, whereas in paper II we detected IL-
10 secretion by 0.09 ± 0.1% from healthy donor B cells. In paper 
II, among patients with GD or HT, we measured 0.32 ± 0.5% and 
0.28 ± 0.8% IL-10 from B cells, respectively. The primary reason 
for this difference could be the method used to detect IL-10. In 
paper I, a cytokine secretion assay was used, whereas in paper II 
intracellular staining was used. In the secretion assay, the cyto-
kine is retained on the surface of a cell by a capture antibody dur-
ing a 45 minute secretion phase (248).  There is a risk of false pos-
itives, if the cell density is too high, which allows a non-secreting 
cell to be in close proximity to a secreting cell and thus capture its 
cytokines (248). However, this has presumably not been the case 
in our study, since the cell density was kept within the recom-
mended cell density for the assay. For intracellular staining, our 
studies used the stimulation period that lasted from 4 hours to 48 
hours with brefeldin A. Brefeldin A is a fungal metabolite, which 
blocks the transport of proteins from the endoplasmic reticulum 
to the Golgi (249,250). It has been shown that brefeldin A affects 
antigen presentation to both CD4+ T cells and CD8+ T cells by in-
hibiting the presentation of protein by MHC class II and I, respec-
tively (251,252). If B cell production of IL-10 is dependent upon in-
teraction with CD4+ T cells, then inhibition of antigen 
presentation by brefeldin A (or interaction between other surface 
molecules on the two cell types) could be the cause of the lower 
IL-10 production detected in paper II.  
A more trivial explanation for the discrepancy between the IL-
10 secretions among the healthy donors in papers I and II is the 
potential contamination of the TG preparation with LPS. It was 
discovered in paper II that the bought TG preparation was con-
taminated with LPS. The contaminating LPS was removed and the 
preparation purified using the Triton X-114 phase separation 
technique outlined by Liu et al (253). Triton X-114, a non-ionic de-
tergent, was chosen due to its high protein recovery rate and abil-
ity to work with small volumes of the TG preparation. Unfortu-
nately, it cannot be determined whether or not the TG 
preparation used in paper I was LPS contaminated since the first 
batch, bought several years earlier, was not tested for LPS con-
tamination. It is well known that LPS, which is a ligand for TLR4 
(254–256), is able to induce pro-inflammatory cytokines, such as 
IFN-γ, TNF-α, IL-12, IL-1β, IL-8, and IL-4 (243,255,257,258). How-
ever, LPS is also able to induce the production of IL-10 and TGF-β 
from monocytes and/or macrophages (243,259,260). These cyto-
kines may have had a bystander effect on our cytokine production 
from our CD4+ T cells and/or B cells. However, in paper I, both 
CD4+ T cells and B cells were isolated, purified and co-cultured 
back together which prevents the bystander effect from the cyto-
kine production from the monocytes.  
Although LPS induces cytokine production it is not clear, when 
reviewing the literature, whether LPS has an effect on human B 
cells. Within the literature there is consensus that TLR4 is ex-
pressed on monocytes and/or macrophages and dendritic cells 
(255). Several studies have reported that B cells from healthy do-
nors express very little or no TLR4 (261–263). However, some re-
cent studies have reported that TLR4 expression is upregulated 
on circulating human B cells during inflammatory diseases, such 
as type 2 diabetes and periodontal disease (264,265). It is postu-
lated that cytokines like IL-4, or the antigen-specific interaction 
between B cells and T cells, or possibly a combination of the two, 
allows the upregulation of TLR4 on B cells (266,267). The function 
of TLR4 on B cells is not yet fully understood, but there is specula-
tion that TLR4 may actually reduce the cells’ ability to produce IL-
10 (267,268). With regard to paper I, if B cells do not express TLR4 
then the LPS from the first TG preparation would not have af-
fected our cytokine production by B cells, or by T cells in the B-
cell/T-cell co-cultures. However, the possibility that the first 
bought TG preparation was LPS contaminated, and that this had 
an effect on the cytokine production from the B cells cannot be 
ruled out. In subsequent studies, TG was purified and determined 
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to be LPS-free to avoid speculation. Therefore, the IL-10 secretion 
detected in B cells in paper II was solely due to TG stimulation.  
Currently, stimuli such as CpG ODN 2006 (TLR9 ligand), LPS 
(TLR4 ligand), PMA/ionomycin, anti-CD40 antibodies, and anti-
IgM antibodies have been reported to induce IL-10 production in 
human B cells (151,154,159,160,162). It is not known how the dif-
ferent B cell subtypes including naïve, memory or transitional B 
cells respond to the different stimuli, and if the different stimuli 
induces different subsets or types of Bregs (269,270). TLRs are im-
portant in initiating the innate immune response, which aids in 
protecting the host against pathogens and act as the first line of 
defense (245,247,255,271). It has been suggested that TLRs such 
as CpG/TLR9 or LPS/TLR4 induces ‘innate-like’ Bregs and thus in-
duces innate-like responses. These ‘innate-like’ Bregs produce IL-
10 and may be important in the first line of defense to reduce ex-
cessive inflammation (11,269,270). In contrast, stimulated with 
anti-CD40 antibodies, CD40L or anti-IgM antibodies may induce 
more ‘acquired type’ Bregs, which may play a role in the adaptive 
immune response (11,269,270). TLRs such as TLR9/CpG may also 
play a role in the adaptive immune system by inducing the ex-
pression of co-stimulatory molecules, cytokines and enhancing 
the antigen presenting ability of APCs (245,255,272). CpG and 
anti-Ig antibodies are presumably the optimal stimuli for inducing 
IL-10 in human B cells since they simultaneously stimulate via 
TLR9 and the BCR (162,269).  
The overall message from our IL-10 and B cell studies is that 
the thyroid self-antigen, TG, is able to induce IL-10 production in 
B cells from healthy donors as well as from patients with GD or 
HT. This finding is novel and may have implications for the patho-
genesis of GD and HT.  
 
Regulatory B cell phenotypes  
Human B cells may have a regulatory role within the immune 
system through the production of IL-10 or TGF-β (273). There con-
tinues to be great interest in phenotyping these potentially regu-
latory B cells. However, no definitive phenotype has yet been as-
signed, and the production of IL-10 is still the best functional 
hallmark or phenotypic marker we have to identify Bregs.  
In paper I, the phenotype of the IL-10-producing B cells 
among healthy donors (also called B10 cells in this thesis) was in-
vestigated. It should be noted that the term ‘B10 cells’ only en-
compasses the Bregs that produce IL-10, but other Breg subsets 
may exist (274). In papers I and II, the CD5+ B10 cells did not rep-
resent the majority since approximately 75% of the B10 cells were 
CD5-. However, it should be noted that in paper I, healthy donor 
B10 cells induced by TG stimulation were more frequently CD5+ 
than were the non-IL-10 producing B cells. CD5 expression on B 
cells has been associated with natural antibody production. Cer-
tain B cells have the ability to bind to both self and foreign anti-
gens and to secrete poly-reactive antibodies also known as natu-
ral antibodies (116,117,275). It has been speculated that these 
poly-reactive antibody-producing B (PAB) cells are CD5+ 
(116,275,276). Within the normal immune response, the CD5+ 
PAB cells and poly-reactive antibodies aid in protecting the host 
from infections by several mechanism. These mechanism include 
activating the complement system and forming the lytic complex, 
by enhancing the phagocytosis of the bacteria and poly-reactive 
Ab complex by macrophages or by having a direct neutralising ef-
fect (112,117,277,278).  Additionally, CD5+ B cells and poly-reac-
tive antibodies may play a role in autoimmunity (277). CD5+ B 
cells have been shown to be the source of autoantibodies against 
the rheumatoid factor and double-stranded DNA in RA and SLE 
patients, hinting towards a pathogenic role for CD5+ B cells (118–
120).    
There is evidence that disease-associated autoantibodies are 
somatically hypermutated, whereas poly-reactive antibodies are 
not (117). The presence of high-affinity autoantibodies against 
double stranded DNA in SLE, and against TG, TPO or TSHR in AITD 
indicates that somatic hypermutation is crucial in the develop-
ment of pathogenic autoantibodies (279,280). There is specula-
tion that poly-reactive antibodies could be the precursors to the 
high affinity pathogenic autoantibodies (277,279,280). 
In paper II, when investigating the whole B-cell population, 
healthy donors had an increased proportion of bulk B cells ex-
pressing CD24hi than GD patients, but this was not the case for 
HT patients. The surface marker CD24 has been associated with 
memory B cells (122), which could indicate that GD patients had a 
lower proportion of memory B cells. When investigating the phe-
notype of B10 cells our initial findings (paper I) showed that 
healthy donors had a higher frequency of IL-10-producing B cells 
expressing CD24hi. This correlated with the findings in paper II 
where healthy donors had increased proportions of CD24hi B10 
cells. Additionally, in paper II we demonstrated that patients with 
GD or HT had a significantly lower frequency of CD24hi B10 cells 
than healthy donors. CD24 has been found to have a role in con-
trolling B cell differentiation and maturation, controlling activa-
tion-induced B cell responses, and in co-stimulation for CD4+ T 
cell growth (281–283). In summary, this indicates that B10 cells 
expressing CD24 are memory cells regulating T-cell function.  
Possible B10 surface markers and phenotypes were expanded 
upon in paper II, including TIM-1+, CD25+, CD24hiCD38hi, and 
CD27+CD43+. HT patients had a significantly higher frequency of 
bulk B cells and B10 cells expressing the marker TIM-1 than 
healthy donors. The function of TIM-1 is in control of CD4+ T cell 
effector differentiation and responses (284,285). TIM-1 was pri-
marily believed to be expressed only on CD4+ T cells and vital for 
regulating Th2 responses. However, new insights have revealed 
that TIM-1 can be expressed on multiple cell types, and that it is 
able to regulate not only Th2 cells but also Th1, Th17, and Tregs 
(285–287). In mice, TIM-1 was shown to be expressed on B cells 
and ligation of TIM-1 induced IL-10 secretion from said B cells 
(153). A study by Liu et al was among the first to show that hu-
man B10 cells were TIM-1+, and that these TIM-1+ B10 cells were 
able to suppress IFN-γ and TNF-α production from CD4+ T cells 
(161). Given the regulatory function of TIM-1, the expression of 
TIM-1 on B cells may aid in the secretion of IL-10 as well as in the 
regulation of auto-reactive T cells in HT pathogenesis.  
Similar to TIM-1, HT patients had a higher frequency of bulk B 
cells and B10 cells expressing the marker CD25 than healthy do-
nors. It should be noted that GD patients had a higher proportion 
of CD25+ B10 cells but did not have the corresponding expression 
on bulk B cells. CD25, the alpha chain of the IL-2 receptor 
(288,289), has been shown to be expressed on human B cells, and 
is expanded in untreated multiple sclerosis patients (290,291). 
CD19+CD25+ B cells are able to secrete IL-10 and suppress CD4+ T 
cell proliferation (157,291). Intriguingly, Kessel et al observed that 
CD19+CD25+ B cells are able to enhance the expression of both 
CTLA-4 and FOXP3 in Tregs (157). This indicates that CD19+CD25+ 
B cells could have some immuno-modulatory/suppressive func-
tions or at least able to enhance immunosuppressive properties in 
circulating Tregs. In addition, the expression of CD25 on Tregs 
(CD25hi or CD25++), allows them to be responsive to IL-2 (9). IL-2 
is needed for the development of Tregs but also for their suppres-
sive function (59,63). Having a functional IL-2 receptor allows the 
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Tregs to act like a ‘sink’ for the IL-2 in the surrounding microenvi-
ronment and thereby, prevents the activation and responses of 
the surrounding T cells (59,64,65,292).  It can be speculated that 
by having an expression of CD25 on B cells, equivalent to Tregs, 
this may allow the CD19+CD25+ B cells to act like a ‘sink’ for IL-2 
and thereby inhibit the surrounding effector T cells’ responses 
similarly to Tregs. Additionally, expression of CD25 may allow B10 
cells to become activated – and regulate the immune response – 
under circumstances with abundance of IL-2 in the environment, 
i.e. in presence of activated effector T cells.  
It should be taken into consideration that in our data, TIM-1+ 
and CD25+ B10 cells did not represent the majority of B10 cells; 
therefore, these markers should not be used to define B10 cells. 
In our findings, there were no differences in the proportion of 
bulk B cells or B10 cells regarding the transitional B cell pheno-
type CD24hiCD38hi between healthy donors and patients with GD 
or HT. Our results do not correlate with the findings of Blair et al 
or Sims et al, who observed that SLE patients had a higher per-
centage of CD24hiCD38hi  B cells than did healthy donors, or with 
Flores-Borja et al who observed that RA patients had a decreased 
percentage of CD24hiCD38hi B cells (131,151,158). The B cell phe-
notype CD24hiCD38hi has been associated with a regulatory func-
tion due to its ability to produce IL-10, limit pro-inflammatory cy-
tokine production as well as control Th1 and Th17 differentiation 
(151,158). CD24hiCD38hi B cells from RA and SLE patients had a 
lower IL-10 production and were functionally impaired in sup-
pressing Th17 differentiation or production of Th1-related cyto-
kines, respectively (151,158). It should be noted that IL-10 pro-
duction has also been detected within the CD24intCD38int and 
CD24hiCD38- B cell phenotypes, indicating that these subsets also 
have some immunosuppressive capability (151). 
The IL-10+ B cells compared to the IL-10- B cells from paper I 
were not enriched with the surface marker CD27 among healthy 
donors. Similarly in paper II, no differences were detected in 
terms of CD27 expression among the bulk B cells or B10 cells in 
healthy donors or in patients with GD or HT. CD27 in combination 
with CD43 has been shown to have some regulatory functions. 
Griffin et al observed that CD27+CD43+CD11b+ B cells were able 
to secrete IL-10 as well as modulate T cell activation (124,293). 
However, no differences were detected among the CD27+CD43+ 
B10 cells between patients and healthy donors. Another pheno-
type, which might be of importance but was not included in our 
studies, is CD24hiCD27+. Iwata et al are among the first to 
demonstrate that B10 cells from healthy donors are found pre-
dominately in the CD24hiCD27+ B cell subpopulation (154). These 
B10 cells had the ability to suppress cytokine production from 
monocytes in an IL-10-dependent manner (154). Inhibition of cy-
tokine production may be due to the fact that IL-10 is able to in-
hibit NF-κB, and NF-κB is crucial for the production of pro-inflam-
matory cytokines including IL-1β, IL-6, IL-8, IL-12 and TNF-α (294–
296). B10 cells with the CD24hiCD27+ phenotype have also been 
detected among GD patients and allergic asthma patients. How-
ever, in these cases a lower proportion of CD24hiCD27+ B cells 
and an impairment of their suppressive function were detected 
(156,159). This indicates that CD24hiCD27+ B cells do have a regu-
latory function, and that a decrease or lack of suppressive func-
tion may facilitate disease development. Further investigation of 
this phenotype is required to determine the potential role it has 
for AITD pathogenesis. 
From our findings it is evident that B10 cells do not express a 
particular surface maker or separate into one clear subpopulation 
or phenotype. This correlates with Bouaziz et al who also discov-
ered that B10 cells can be found in multiple subpopulations (162). 
Given the complexity of this field, it will not be sufficient to use 
only surface markers or even IL-10 to characterize regulatory B 
cells. A combination of phenotype, function and even genetic pro-
file will be needed to truly define a human regulatory B cell (297).  
 
Antigen presenting ability of B cells and monocytes  
Antigen presenting cells (APC) include B cells, mono-
cytes/macrophages and dendritic cells (109,298–300). In paper I, 
the efficacy of monocytes and B cells to act as antigen-presenting 
cells were studied. Depletion of monocytes from whole PBMC sig-
nificantly reduced the secretion of several cytokines such as TNF-
α, IL-6, and even IL-10, while B-cell depletion did not have the 
same effect. With B cell depletion, only a modest reduction in IL-
10 was detected. This could indicate that monocytes were a ma-
jor source of IL-10, TNF-α and IL-6 (74,243,301). Additionally, de-
pleting monocytes dramatically decreased CD4+ T cell prolifera-
tion, which was not observed when B cells were depleted. This 
shows that, in our study, monocytes were more efficient at anti-
gen presentation than B cells. This is in accordance with a study 
by Beck et al who observed that monocytes were more efficient 
than B cells at stimulating human CD4+ T cells and are thus a 
more efficient antigen presenting cell (302). Intriguingly, a study 
by Constant et al showed that peptides were preferentially taken 
up by dendritic cells and B cells preferred the uptake of whole 
proteins (303).  
B cells are competent APC in terms of priming CD4+ T cells 
and may be the predominant antigen-presenting cells under cir-
cumstances where the antigen is scarce, due to their ability to up-
concentrate antigens on the cell surface via BCR (107,304). In pa-
per I, human B cells were purified and preloaded with the TG anti-
gen and then co-cultured with CD4+ T cells. Subsequently, we 
were able to measure IL-10 secretion by the co-cultured CD4+ T 
cells. This indicates that the purified B cells were acting as anti-
gen-presenting cells. A study by Guo et al was the first to demon-
strate the existence of TPO-specific B cells and the ability of these 
B cells to present TPO to T cells, as indicated by the induction of T 
cell proliferation in murine spleen cell cultures (305). Nielsen et al 
demonstrated that TG was able to induce proliferation in CD4+ T 
cells in cultures of human PBMC. The removal of B cells from in-
tact PBMC markedly reduced this proliferation indicating that B 
cells were acting as antigen-presenting cells in terms of TG 
presentation (278). In paper I, the TG-preloaded B cells induced a 
protective response in the CD4+ T cells by the secretion of IL-10. 
In contrast, B cells preloaded with TT induced a pro-inflammatory 
response in the co-cultured CD4+ T cells.    
In paper III, intact PBMC were investigated instead of purified 
B cells and CD4+ T cells. Therefore, it could not be determined 
whether it was the B cells or the monocytes that acted as the 
main antigen-presenting cell. However, since depleting mono-
cytes had the biggest effect on cytokine production and prolifera-
tion, it can be speculated that it was the monocytes that were 
acting as the main antigen-presenting cells in paper III.  
 
The T helper cell study  
IL-10 production by CD4+ T cells 
In this thesis, IL-10-producing CD4+ T cells are referred to as 
Th10 cells. The term ‘Th10’ has been used in the literature to de-
note all IL-10-producing Th cells irrespective of their origin (306). 
As mentioned earlier, the biological activities of IL-10 are far-
reaching. IL-10 has also been shown to have both indirect and di-
rect effects on CD4+ T cells. Indirectly, IL-10 can inhibit the pro-
duction of key cytokines such as IFN-γ or IL-4 from monocytes or 
macrophages which could affect Th1 or Th2 differentiation and 
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response, thus regulating Th1 and Th2 responses via antigen pre-
senting cells (74–76). Studies have shown that IL-10 may also 
downregulate MHC class II expression as well as co-stimulatory 
molecules on monocytes/macrophages resulting in an impaired 
capacity to stimulate T cells (243,307). Directly, IL-10 may also 
suppress the cytokine production and the proliferation of CD4+ T 
cells, as well as induce Tregs (74–76). 
In paper I, a significantly higher proportion of CD4+ T cells in 
healthy donors were able to secrete IL-10 after stimulation with 
the thyroid self-antigen TG than after stimulation with the foreign 
recall antigen TT. On the other hand, TT induced the secretion of 
Th1-type pro-inflammatory cytokines and minimal IL-10 secretion. 
Once again in paper III, TG was able to induce IL-10 secretion 
above the background within CD4+ T cells from healthy donors as 
well as in patients with GD or HT.    
In paper III, CD4+ T cells were divided into naïve 
(CD45RA+CD45R0-) or memory (CD45RA-CD45R0+) cell compart-
ments and TPO, a thyroid self-antigen, and E. coli LPS, a foreign 
control antigen, were used to induce cytokine production. Our 
data show that TPO and E. coli LPS were able to induce IL-10 pro-
duction above the background in both CD4+ T cell compartments 
in healthy donors as well as in both patient groups. In addition, no 
differences were found in the proportion of Th10 cells between 
the healthy donors and patients with GD or HT after polyclonal 
stimulation with anti-CD3/anti-CD28 antibodies. Our findings 
show that similar proportions of Th10 cells were detected be-
tween patients with GD or HT and healthy donors thereby, indi-
cating that patients were not impaired in the ability of inducing a 
regulatory T-cell response. It should be noted that the Th10 cells 
detected in our studies may in fact encompass both iTregs and 
nTregs because our staining protocol did not discriminate be-
tween these two subsets. In the literature, there are conflicting 
results in terms of the frequency of Tregs in AITD patients. Glick 
et al, who grouped GD and HT as AITD, observed that the fre-
quency of CD4+CD25hi Tregs were similar between AITD patients 
and healthy donors (308). Comparable results were observed by 
Pan et al in GD patients when compared against healthy donors 
(309). Notably, these Tregs may be nTregs and were characterized 
and measured solely on the basis of phenotype. Marazuela et al 
observed that AITD patients had a significantly higher frequency 
than healthy donors of CD4+GITR+ and CD4+FOXP3+ as well as 
CD4+IL-10+ in the peripheral blood, which they claim represents 
nTregs and iTregs, respectively. (310). Our data showed that pa-
tients with GD or HT had an adequate number of circulating Th10 
cells, but whether these Th10 cells function as well as healthy do-
nor Th10 cells in suppressing cytokine production or proliferation 
was not measured in our study. Two studies have demonstrated 
that CD4+CD25hi Tregs from AITD patients were less able to in-
hibit proliferation than their healthy donor counterparts 
(308,310).   
The above studies were carried out in the peripheral blood, 
and the situation may not be the same in the thyroid tissue. A 
study by Nakano et al, who grouped GD and HT as AITD, showed a 
lower proportion of CD4+CD25+ Tregs among the intra-thyroidal 
lymphocytes in the thyroid than among blood lymphocytes (311).  
Overall, our results show that thyroid self-antigens are able to 
induce IL-10 secretion in CD4+ T cells in healthy donors and in pa-
tients with GD or HT. Additionally, patients with GD or HT were 
not impaired or deficient in inducing an immuno-regulatory re-
sponse as noted by the similar proportions of Th10 cells in 
healthy donors and both patient groups.  
 
IL-17 production by CD4+ T cells 
HT has always been believed to be a Th1-mediated autoim-
mune disease (205,209), due to the increased production of IFN-
γ, IL-2 and TNF-α detected among HT patients (233–236). How-
ever, many autoimmune diseases such as RA, inflammatory bowel 
disease, multiple sclerosis and possibly even HT (37,38) may in-
stead be driven by Th17 cells and their production of IL-17 rather 
than Th1 cells and IFN-γ. 
After incubation of intact PBMC with anti-CD3/anti-CD28 anti-
bodies, in paper III, the proportion of Th17 cells did not differ be-
tween each patient group and healthy donors. However, incuba-
tion with the thyroid self-antigen TPO did induce higher 
proportions of Th17 cells in the naïve CD4+ T cell compartment of 
HT patients than of healthy donors or GD patients. This finding is 
novel, as Th17 induction by thyroid self-antigens has not been re-
ported previously. This indicates that HT patients have a higher 
frequency of self-antigen specific Th17 cells than healthy donors, 
even though the frequency of dedicated Th17 cells, in general, is 
not elevated in patients. 
In contrast to our results, Nanba et al and Figeuroa-Vega et al 
showed that a higher proportion of Th17 cells were detected in 
peripheral blood from HT patients than in healthy donors or GD 
patients after polyclonal stimulation with PMA/ionomycin 
(40,41). Shi et al also observed a higher baseline mRNA level of IL-
17 among PBMC from HT patients than among PBMC from 
healthy donors (39).  
It should be noted that the increase in the proportion of Th17 
cells was not restricted to the self-antigen TPO. E. coli LPS, used 
as a foreign control antigen, was also able to increase the propor-
tions of both naïve and memory Th17 cells in HT patients, com-
pared to those of healthy controls or GD patients. This correlated 
well with McAleer et al who observed that E. coli LPS expanded 
pre-committed Th17 cells instead of de novo induction of Th17 
differentiation (312,313).  
Our data indicates that irrespective of the stimulus, TPO or E. 
coli LPS, CD4+´T  cells from HT patients are more prone to differ-
entiate into IL-17-producing cells than CD4+ T cells from healthy 
donors.  
 
Th17/Th10 ratio and Th17 differentiation 
Th10 cells and Th17 cells have been investigated separately in 
AITD, but this study is the first to analyze their relative frequen-
cies together. In paper III, we observed that Th0 cells among the 
healthy donors preferentially differentiated into Th10 cells, 
whereas for patients with GD or HT, Th0 cells preferentially differ-
entiated into Th17 cells. The preferential differentiation of Th0 
cells into Th17 cells in AITD patients could be a result of the sur-
rounding microenvironment. Therefore, we quantified IL-1β, IL-6 
and TGF-β1 in the culture supernatants knowing that the local cy-
tokine environment is crucial to Th17 differentiation. However, 
which cytokines are the most important for Th17 differentiation is 
still under debate. To date, several cytokines have been impli-
cated in Th17-cell differentiation, including IL-1β, IL-6, IL-21, IL-23, 
TNF-α and TGF-β (37,42–46,314). We found that HT patients had 
a higher baseline concentration of IL-6 and TGF-β1 in unstimu-
lated PBMC cultures than healthy donors. It should be noted that 
TGF-β1 was higher in HT patients than healthy donors, irrespec-
tive of whether TG, TPO or E. coli LPS was used as the stimulus. 
The higher baseline concentration of IL-6 and TGF-β1 may sup-
port the increased differentiation of Th17 cells in the HT patient 
group.  
The role that TGF-β may play in Th17 differentiation is intri-
guing. TGF-β is a regulatory cytokine that aids in the differentia-
tion of inducible Tregs (54,315). TGF-β along with IL-6 may have a 
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more direct role in Th17 differentiation by inducing the expres-
sion of RORγt and RORα (49,316). However, TGF-β may also have 
an indirect role with Th17 differentiation by limiting Th1 differen-
tiation and thereby allowing the differentiation of Th17 cells (48). 
Moreover, the concentration of TGF-β might also be crucial for 
Th17 differentiation, where low concentrations (1-10ng/mL) in-
duces Th17 differentiation, and higher concentrations (50ng/mL) 
inhibits Th17 differentiation and promotes Treg differentiation 
(95,317).   
The imbalance between pro-inflammatory and anti-inflamma-
tory CD4+ T cell subsets, such as Th17, and Treg subsets, respec-
tively, may be one of the pathogenic mechanisms in autoimmune 
disease (36). This gives credence to our hypothesis that the 
skewed Th17:Th10 ratio detected in AITD patients may play a role 
in AITD pathogenesis.  
 
FOXP3 and Th17 plasticity  
There is a high degree of plasticity in the Th17/Treg differenti-
ation pathways, but the biological relevance for this is still un-
clear. Studies have shown that FOXP3+ Tregs are able to produce 
IL-17 after PMA/ionomycin stimulation, or in an IL-1β-dependent 
way (101–104). It has also been demonstrated that these IL-17-
producing FOXP3+ Tregs were expressing the Th17-specific tran-
scription factor RORyt constitutively alongside the expression of 
the Treg-specific transcription factor FOXP3 (102,104). If 
FOXP3+Tregs are able to produce IL-17 or even differentiate into 
Th17 cells that might help to explain why in some autoimmune 
diseases a higher percentage of Th17 cells are detected than in 
healthy individuals. It is still not clear whether these IL-
17+FOXP3+ Tregs are able to maintain their suppressive function 
due to conflicting results (103,104).  
In our study, both patient groups had a higher constitutive ex-
pression of FOXP3Δ2, but not of total FOXP3, than healthy donors 
in the unstimulated PBMC cultures. Thus, the patient groups ex-
pressed relatively more of the FOXP3Δ2 splice variant than 
healthy donors. CD4 was chosen as the housekeeping gene be-
cause the expression of CD4 does not alter after stimulation 
(318). Additionally, FOXP3 is expressed by CD4+ T cells and using 
a house-keeping gene that is specific to the cell population being 
studied is preferred.  Full length FOXP3 functions as suppressors 
of RORγt (RORC, human ortholog) and RORα, as well as of the 
NFAT and NF-κB by binding to them and inhibiting their biological 
activity. Binding of FOXP3 to RORγt and RORα prevents Th17 dif-
ferentiation, and allows the differentiation of Tregs (94,95,97). In 
contrast, FOXP3Δ2 is unable to suppress RORγt and RORα, as well 
as NF-κB because it is unable to bind (93–97,319). Mouse studies 
have shown that exon 2 is crucial for the binding of FOXP3 to 
RORγt or RORα or NF-κB (94,97) and is thought to be the vital part 
of the repressor domain (96). The inability of FOXP3Δ2 to bind to 
and inhibit RORγt, RORα and NF-κB relies upon the missing exon 
2. RORγt is the prevailing transcription factor for Th17 cells, and 
RORα is upregulated in Th17 cells due to the presence of certain 
cytokines in the local cytokine environment (49,316). Therefore 
the inability of FOXP3Δ2 to bind and inhibit RORγt and RORα 
would allow the differentiation of Th17 cells, and could result in 
the skewed Th17: Th10 cell ratio observed in paper III.  
In summary, our study shows that patients with GD or HT 
have a higher constitutive expression of FOXP3Δ2 than healthy 
donors. This elevated expression of FOXP3Δ2 in HT patients may 
help to explain the preferential differentiation of Th17 cells in HT 
patients in paper III.   
 
Limitations of the study  
Considerations have to be made because all of my experi-
ments in all three papers (I, II and III) were carried out on isolated 
lymphocytes from the peripheral blood. These may not be func-
tionally or phenotypically similar to the intra-thyroidal lympho-
cytes driving the disease.  
A limitation of our studies was the sparse number of samples 
per group. For many explorative studies, such as the ones we car-
ried out, a sample size of 10-15 is the norm. In all our papers (I, II 
and III) we wanted to illustrate qualitative differences in the cyto-
kine production between patients with GD or HT and healthy do-
nors. A previous study by Glick et al, examining Tregs in AITD, had 
7 GD patients and 13 HT patients, while Figueroa-Vega et al, stud-
ying Th17 cells in AITD, had 8 GD patients and 18 HT patients 
(41,308). The size of each sample group (paper II: 12 healthy do-
nors, 12 GD patients; 12 HT patients; paper III: 15 healthy donors; 
11 GD patients; 10 HT patients) and power calculation was based 
on previous studies in our group where significant differences 
were observed with 10-15 subjects in each group (320–322). 
However, with small sample groups and a low study power, there 
is a risk of making a type I or a type II error.  
Another limitation was that the majority of the GD or HT pa-
tients that were recruited for papers II and III were treated with 
either methimazole or levothyroxine for varying periods of time 
before blood collection and participation in this PhD study. It 
should be taken into consideration that the cytokine production 
for the treated GD or HT patients might be altered due to anti-
thyroid drugs, and therefore might be more similar to the cyto-
kine production detected for healthy donors. This might have led 
us to underestimate the differences in cytokine production be-
tween patients and healthy donors. Several reports have linked 
an association between anti-thyroid medication and cytokine pro-
duction; Weiss et al reported that anti-thyroid drugs inhibited the 
proper functioning of lymphocytes (323). Thionamides, a class of 
anti-thyroid drugs, have been shown to inhibit cytokine produc-
tion due to the suppression of NF-κB (324). In contrast, Volpe et al 
reported that the thyroid status, itself, might have an effect on 
the immune system (325). Severe hyperthyroidism might affect 
the immune system by altering the numbers and activation status 
of CD4+ and CD8+ T cells, by increasing the serum concentrations 
of IL-2, as well as by altering the responsiveness of CD4+ T cells to 
the thyroid self-antigens (325).  
However, it should be noted that all patients with GD or HT 
had antibody titres well above the normal range for either anti-
TSHR or anti-TPO respectively at the time of blood sampling. This 
was an inclusion criterion for the studies in papers II and III. This 
indicates that all patients were immunologically active, even 
though some were receiving anti-thyroid medication or thyroid 
hormone. 
 
Conclusions  
Overall Conclusions of the study  
One of the main findings of this PhD study is that the human 
thyroid self-antigen TG is able to induce antigen-specific produc-
tion of IL-10 in both CD19+ B cells and CD4+ T cells, in healthy do-
nors as well as in patients with GD or HT.  Moreover, TPO, an-
other thyroid specific self-antigen, induced higher frequencies of 
Th17 cells within the naïve CD4+ T-cell compartment in HT pa-
tients than healthy donors. This increased frequency or skewing 
towards Th17 cells in HT patients could be due to an elevated 
baseline production of IL-6 and TGF-β1 by PBMC or to an in-
creased expression of mRNA encoding FOXP3Δ2. Notably, the 
proportions of Th10 cells of GD or HT patients were similar to 
those in healthy controls. 
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Furthermore, we demonstrated that patients with GD or HT 
were not impaired or deficient with regards to inducing an im-
muno-regulatory response in terms of IL-10 production by CD19+ 
B cells. IL-10 production by B10 cells was similar between healthy 
donors and patients with GD or HT, irrespective of the stimulus 
used.  We also showed that B10 cells among healthy donors and 
patients with GD or HT did not separate into one clearly defined 
phenotypic subgroup, nor did they express the surface markers 
that have previously been associated with B10 cells. We did, how-
ever, find that B10 cells from HT patients and GD patients had a 
frequency of B10 cells expressing CD25 and TIM-1.  
Thus, these studies have provided insights and extended our 
understanding of the pathogenesis of GD and HT in terms of the 
immune system’s reaction to thyroid self-antigens.  
 
Perspectives 
There are still so many unanswered questions that remain to 
be answered with regards to the pathogenesis of AITD. It is still 
not clear as to why thyroid autoimmunity starts to begin with and 
by what mechanisms autoimmunity is allowed to progress. Some 
future experiments to aid in our understanding of the pathogene-
sis of AITD could be:  
 To measure the frequency of Th10 and Th17 cells as well as 
their cytokine products IL-10 and IL-17 in the thyroid tissue 
of AITD patients.  
 To measure the functionality of the IL-10-producing CD4+ T 
cells or IL-10-producing B cells, in terms of inhibiting cytokine 
production, proliferation or differentiation of effector CD4+ 
T cells from AITD patients in the peripheral blood and thyroid 
tissue.  
 To characterize the phenotype of B10 cells in the thyroid tis-
sue of AITD patients.  
 To measure other anti-inflammatory cytokines such as TGF-β 
and/or IL-35. IL-35 has recently been shown to have a regula-
tory role in autoimmunity (326,327).  
 
From our data HT patients had a higher frequency of Th17 
cells and IL-17 production. Inhibiting the Th17/IL-17 axis might be 
a useful therapeutic treatment. Currently, there are three anti-IL-
17A drugs, namely secukinumab, ixekizumab and brodalumab, 
undergoing clinical trials (328). Secukinumab is a fully human anti-
IL-17A monoclonal antibody (mAb) with IgG1 subtype, ixekizumab 
is a humanized anti-IL-17A mAb, whereas brodalumab is a fully 
human anti-IL-17RA mAb, which is directed against the IL-17A re-
ceptor (328). These therapeutic agents allow the inhibition of IL-
17 production as well as the blocking of IL-17A receptor. These 
therapeutic agents have shown great promise in reducing IL-17 
production in various autoimmune diseases such as RA, psoriasis 
and Crohn’s disease (328,329). These therapeutic agents might 
also have a positive effect in patients with HT by blocking the pro-
duction of IL-17 or its receptor. Intriguingly, there is also evidence 
that therapeutic agents can be produced to inhibit the transcrip-
tion factors ROR-γt and ROR-α, which are central to Th17 differ-
entiation. If these transcription factors can be blocked that would 
inhibit Th17 differentiation and reduce IL-17 production (330).  
 
Summary 
Autoimmune diseases occur due to faulty self-tolerance. 
Graves’ disease (GD) and Hashimoto’s thyroiditis (HT) are classic 
examples of organ-specific autoimmune diseases. GD is an auto-
antibody-mediated disease where autoantibodies are produced 
against the thyroid stimulating hormone receptor (TSHR). HT is 
primarily a T-cell mediated disease, and whether B cells play a 
pathogenic role in the pathogenesis is still unclear. Both GD and 
HT are characterized by infiltration of the thyroid gland by self-re-
active T cells and B cells.   
In the first paper of this thesis, the role of regulatory B cells 
(Bregs) and regulatory T cells (Tregs) were investigated in the con-
text of GD and HT.  First, we studied the role of the thyroid self-
antigen, thyroglobulin (TG) in healthy donors. The self-antigen TG, 
but not the foreign recall antigen tetanus toxoid (TT), was able to 
induce interleukin 10 (IL-10) secretion by B cells and CD4+ T cells. 
These IL-10 producing B cells (B10 cells) from healthy donors 
were enriched with the CD5+ and CD24hi phenotype. In addition, 
TG was able to induce IL-6 production by B cells. In contrast, TT 
induced production of Th1-type pro-inflammatory cytokines in-
cluding interferon-gamma (IFN-γ) and IL-2.  
In the second paper, the frequency and phenotype of B10 was 
investigated in healthy donors and patients with GD or HT.  The 
frequencies of B10 cells were similar in the three groups, irrespec-
tive of whether IL-10 was induced by a combination of phorbol 
12-myristate 13-acetate (PMA) and ionomycin, by CpG oligodeox-
ynucletodies (ODN) 2006, or by TG. Several phenotypes have 
been associated with B10 cells such as CD5+, CD25+, TIM-1+, 
CD24hiCD38hi and CD27+CD43+. We found that larger propor-
tions of B10 cells in patients with GD or HT were CD25+ and TIM-
1+ than B10 cells in healthy donors. In healthy donors, B10 cells 
were CD24hiCD38-, whereas for HT patients these cells were pri-
marily CD24intCD38int. For GD patients, we found lower propor-
tions of B10 cells within the CD27+CD43- and CD27-CD43- frac-
tions than for healthy donors. Our data show that GD and HT are 
not associated with decreased frequencies of B10 cells. Accord-
ingly, B10 cells may not be confined to one phenotype or subset 
of B cells.   
In the third paper, we studied the balance between IL-17-pro-
ducing CD4+ T cells (Th17 cells) and IL-10-producing CD4+ T cells 
(Th10 cells) in healthy donors and patients with GD or HT. In HT 
patients, we found increased proportions of naïve Th17 cells after 
stimulation with the thyroid self-antigen thyroid peroxidase (TPO) 
and the Escherichia coli lipopolysaccharide (E. coli LPS).  The pro-
portions of Th10 cells were similar in healthy donors and in HT pa-
tients after antigen-specific stimulation. After TG stimulation, an 
increased Th17:Th10 ratio was found in HT patients within the na-
ïve T cell compartment. Taken together, these data indicate that 
the thyroid self-antigens TG and TPO induced a skewed 
Th17:Th10 differentiation in HT patients. IL-6 and TGF-β have 
been reported to be important for human Th17 differentiation 
and, accordingly, HT patients showed higher baseline production 
of IL-6 and TGF-β1 than healthy donors. Moreover, the baseline 
expression of mRNA encoding the transcription factor Forkhead 
box protein 3 (FOXP3) was similar in HT patients and healthy do-
nors, but HT patients displayed higher constitutive expression of 
the splice variant FOXP3Δ2, lacking exon 2, than healthy donors. 
Full-length FOXP3 has been shown to inhibit Th17 differentiation, 
while FOXP3Δ2 does not. Thus, increased IL-6 and TGF-β1 in the 
microenvironment and the increased expression of FOXP3Δ2 may 
contribute to the skewing of Th17 cells in HT patients.  
In conclusion, the human thyroid self-antigen TG is able to in-
duce antigen-specific production of IL-10 in CD19+ B cells and 
CD4+ T cells among healthy donors and patients with GD or HT. 
Our data indicates that patients with GD or HT were not impaired 
in producing IL-10 and thus an immuno-regulatory response. Ad-
ditionally, TPO, a thyroid self-antigen, induced a higher frequency 
of Th17 cells in HT. This indicates that Th17 cells may play an im-
portant role in HT pathogenesis. 
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